title: Temsirolimus in overtreated metastatic renal cancer with subsequent use of sunitinib: A case report.
abstract: During the last decade, we have been developing new therapeutic strategies for the treatment of renal cancer, based on knowledge derived from molecular biology. We report a case of long-term renal metastatic cancer progression despite therapy with sunitinib and interleukin, which are the most active drugs in renal cancer. Disease stabilization for 58 weeks was achieved upon sequential use of temsirolimus, following the occurrence of disease progression during angiogenic therapy. The patient demonstrated excellent tolerance without marked symptoms for 10 months. Hypothyroidism and mumps-related adverse events were present. The survival time from diagnosis to lung metastasis was 8 years. Thus, this case demonstrates promising therapeutic effects of the sequential use of tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors during different stages of the disease.
authors.affiliation: Oncology Department, Hospital Clínico Universitario San Cecilio, Avenida, Granada 18012, Spain.
authors.forename: José Miguel
authors.initials: JM
authors.lastname: Jurado
authors.forename: Irene
authors.initials: I
authors.lastname: Zarcos
authors.forename: Mayte
authors.initials: M
authors.lastname: Delgado
authors.forename: Isabel
authors.initials: I
authors.lastname: Blancas
authors.forename: Marta
authors.initials: M
authors.lastname: Legerén
authors.forename: José Luis
authors.initials: JL
authors.lastname: García-Puche
keywords: mTOR inhibitors; metastatic renal carcinoma; temsirolimus